source
- AbbVie’s eczema antibody shows statistically significant benefit in Phase 2 trialAbbVie presented Phase 2 results for its experimental eczema treatment, an anti‑IL‑13 antibody named Zumilokibart. The study met its primary endpoints, demonstrating statistically significant impr…
- Beam Therapeutics files lawsuit accusing former scientist of stealing IP to launch Chinese biotech ventureBeam Therapeutics has initiated legal action alleging that a former employee misappropriated proprietary gene-editing technology. The company claims the scientist used the stolen information to co…